Medicus Pharma reports principal investigator validation of Phase 2 data

Medicus Pharma (MDCX) reported independent clinical validation of its Phase 2 SkinJect dataset from Dr. Babar Rao, principal investigator of the SKNJCT-003 study. “In my view as principal investigator, the dataset is clinically meaningful, supports continued development, and justifies regulatory engagement and further trials,” said Dr. Rao. The company noted the 200 microgram cohort at Day 57 demonstrated an approximately 80% overall response rate. These findings support the company’s selection of the 200 microgram dose as the lead regimen for further development.